贵州三力: 贵州三力制药股份有限公司第四届监事会第十二次会议决议公告

Group 1 - The core point of the announcement is that the company plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration [1][2] - The total amount of the proposed technology contract is 150 million RMB, which will be paid in installments according to the contract terms [2] - The signing of the contract does not require approval from the shareholders' meeting and does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2] Group 2 - The decision was made during the 12th meeting of the 4th Supervisory Board, which was held in compliance with legal and regulatory requirements [1] - The voting results showed unanimous support with 3 votes in favor, and no votes against or abstaining [2] - The contract aligns with the company's long-term strategic goals and is expected to have no significant impact on the current financial status or operating performance [2]